FDA approves Pfizer's Tukysa as front-line maintenance for HER2+ breast cancer

October 7, 2026 12:57 PM

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration has approved Tukysa (tucatinib) in combination with trastuzumab ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found